Smith ALW, Harmer CJ, Cowen PJ, et al. The serotonin 1A (5-HT(1A)) receptor as a pharmacological target in depression. CNS Drugs. 2023;37(7):571–85.

Article  CAS  PubMed  Google Scholar 

Bielski RJ, Cunningham L, Horrigan JP, et al. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008;69(4):571–7.

Article  CAS  PubMed  Google Scholar 

World Health Organisation. Depressive disorder (depression). 2023. https://www.who.int/. Accessed 25 Oct 2023.

American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts. 2019. https://www.apa.org/. Accessed 25 Oct 2023.

Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(3):243–9.

Article  CAS  PubMed  Google Scholar 

Malhi GS, Bell E, Boyce P, et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. Bipolar Disord. 2020;22(8):805–21.

Article  PubMed  Google Scholar 

Fabre-Kramer Pharmaceuticals Inc. Gepirone ER: US prescribing information 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 3 Oct 2023.

Fabre-Kramer Pharmaceuticals Inc. Fabre-Kramer Pharmaceuticals announces FDA approval of EXXUA™, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults [media release]. 28 Sep 2023. https://fabrekramer.com/.

GlaxoSmithKline, Fabre-Kramer Pharmaceuticals Inc. GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder [media release]. 8 Feb 2007. http://www.fabrekramer.com.

PharmaTimes. FDA issues non-approvable letter for GlaxoSmithKline Fabre-Kramer's gepirone ER [media release]. 5 Nov 2007. https://www.pharmatimes.com/.

Fabre-Kramer Pharmaceuticals Inc. Fabre-Kramer looks forward to FDA's decision on gepirone ER for the treatment of major depressive disorder [media release]. 2 Dec 2015. http://www.fabrekramer.com/.

Fabre-Kramer Pharmaceuticals Inc. Fabre-Kramer re-acquires gepirone ER rights from Organon [media release]. 15 Jun 2005. http://www.prnewswire.com.

Chojnacka-Wójcik E, Tatarczyńska E, Gołembiowska K, et al. Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology. 1991;30(7):711–7.

Article  PubMed  Google Scholar 

Timmer CJ, Sitsen JMA. Single- and multiple-dose pharmacokinetics and tolerability of gepirone extended-release. Clin Drug Investig. 2002;22(12):819–26.

Article  CAS  Google Scholar 

Fabre LF, Timmer CJ. Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. Curr Ther Res Clin Exp. 2003;64(8):580–98.

Article  PubMed  PubMed Central  Google Scholar 

Dogterom P, Huisman J, Gellert R, et al. Pharmacokinetics of gepirone in subjects with normal renal function and in patients with chronic renal dysfunction. Clin Drug Invest. 2002;22(8):513–22.

Article  CAS  Google Scholar 

Lam YWF, Ereshefsky L, Port A, et al. Effects of rifampin on the disposition of gepirone ER and its metabolites. Open Drug Metabolism Journal. 2009;3:1–7.

Article  Google Scholar 

Keller MB, Ruwe FJ, Janssens CJ, et al. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol. 2005;25(1):79–84.

Article  CAS  PubMed  Google Scholar 

Fabre LF, Brown CS, Smith LC, et al. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med. 2011;8(5):1411–9.

Article  CAS  PubMed  Google Scholar 

Fabre LF, Clayton AH, Smith LC, et al. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. J Sex Med. 2012;9(3):821–9.

Article  PubMed  Google Scholar